BenevolentAI Investor Presentation Deck
Principles and benefits of our technology approach
!
Industry R&D
CHALLENGES
Half of clinical failures due to poor
understanding of disease
biology/mechanisms
• Siloed disease-specific approach -
scientists can't connect or infer
shared mechanisms across diseases
Single modality data - each with
limitations and biases
. Often limited understanding of
what drives lab phenotypic effects
• Much of target discovery is
serendipitous, not a scalable or
repeatable process
BenevolentAl's
APPROACH
1 Biology first
2
Comprehensive
data approach
3 Hypothesis driven
4 Software based
iii
M
Benevolent Platform™
BenevolentAl
BENEFITS
DISEASE-AGNOSTIC
MODALITY-AGNOSTIC
ENABLES NOVEL TARGET ID
ACCELERATES DISCOVERY
SCALABLE & REPEATABLE
POTENTIAL TO
INCREASE PROBABILITY
OF SUCCESS
Benevolent 33View entire presentation